ASAP.F Stock Overview
Through its subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive interspinous fusion systems and devices in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Aurora Spine Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.20 |
| 52 Week High | CA$0.34 |
| 52 Week Low | CA$0.16 |
| Beta | 0.72 |
| 11 Month Change | 12.51% |
| 3 Month Change | -21.04% |
| 1 Year Change | 1.54% |
| 33 Year Change | -62.89% |
| 5 Year Change | -38.99% |
| Change since IPO | -84.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| ASAP.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 3.8% | -0.3% | 0.3% |
| 1Y | 1.5% | -1.3% | 22.5% |
Return vs Industry: ASAP.F exceeded the US Medical Equipment industry which returned -1.3% over the past year.
Return vs Market: ASAP.F underperformed the US Market which returned 22.5% over the past year.
Price Volatility
| ASAP.F volatility | |
|---|---|
| ASAP.F Average Weekly Movement | 12.0% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ASAP.F's share price has been volatile over the past 3 months.
Volatility Over Time: ASAP.F's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | Trent Northcutt | www.aurora-spine.com |
Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive interspinous fusion systems and devices in Canada. The company offers interspinous process lumbar fusion devices, such as the ZIP, ZIP ULTRA, ZIP LP, and ZIP-51 for patients suffering from degenerative disc diseases; and Ti-Coated polyether ether ketone interbody cages, which provide spacing and stability between the vertebrae while bone grows to complete the fusion process. It also provides sterile-packed titanium plasma spray coated spinal infusion implants for bone growth, as well as interbody products, such as EOS, VOX, Echo, Echo SD, and EchoXL for the lumbar section of the spine, and discovery for cervical procedures.
Aurora Spine Corporation Fundamentals Summary
| ASAP.F fundamental statistics | |
|---|---|
| Market cap | US$17.15m |
| Earnings (TTM) | -US$1.28m |
| Revenue (TTM) | US$15.58m |
1.1x
P/S Ratio-13.4x
P/E RatioIs ASAP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASAP.F income statement (TTM) | |
|---|---|
| Revenue | US$15.58m |
| Cost of Revenue | US$6.41m |
| Gross Profit | US$9.17m |
| Other Expenses | US$10.45m |
| Earnings | -US$1.28m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.017 |
| Gross Margin | 58.86% |
| Net Profit Margin | -8.25% |
| Debt/Equity Ratio | 51.2% |
How did ASAP.F perform over the long term?
See historical performance and comparison